Another single institution study studied nivolumab in patients with R/R pediatric brain tumors and concluded that immune checkpoint inhibitors have better outcomes in brain tumors with high PD-L1 expression and a high tumor mutation burden as evidenced by a better median survival in those patients who were PD-L1 positive [17]. The gene discussed is CD274; the disease is brain neoplasm.